4-((3R,5R,6S,8S,9S,10R,13R,14S,17R)-3,6-Dihydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-yl)-pentanoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 4-((3R,5R,6S,8S,9S,10R,13R,14S,17R)-3,6-Dihydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-yl)-pentanoic acid
• 英文别名: 6alpha,20xi-Murideoxycholic acid；4-[(3R,5R,6S,8S,9S,10R,13R,14S,17R)-3,6-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
• 化学式: C₂₄H₄₀O₄
• 分子量: 392.579
• InChiKey: DGABKXLVXPYZII-LJESHCOTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-((3R,5R,6S,8S,9S,10R,13R,14S,17R)-3,6-Dihydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-yl)-pentanoic acid 在 盐酸 、 2-碘酰基苯甲酸 作用下， 以 水 、 叔丁醇 为溶剂， 反应 5.0h， 生成
  参考文献：
  名称：

  一种鼠胆酸的制备方法

  摘要：

  本发明涉及药物合成技术领域，尤其是涉及一种鼠胆酸的制备方法。所述鼠胆酸的制备方法，以3α，6α‑二羟基‑5β‑胆烷酸为原料经烷基酯化，6位、3位选择性氧化，溴化反应，取代反应，6位还原，水解得到鼠胆酸。本发明通过上述合成路线制备得到鼠胆酸，即3α，6β，7β‑三羟基‑5α‑胆烷酸，原料来源广泛，供应充足；并且，经过上述步骤得到的鼠胆酸的产率高，可达24.5％，适合大量制备，可为后续的相关研究提供数据支持及参考。

  公开号：

  CN109369765B

文献信息

• STEROL ANALOGS AND USES THEREOF
  申请人：ModernaTX, Inc.

  公开号：EP3852764A1

  公开（公告）日：2021-07-28
• INJECTABLE COMPOSITION FOR LOCALIZED FAT REDUCTION WITHOUT PAIN, EDEMA, AND SIDE EFFECTS, AND METHOD FOR PREPARING SAME
  申请人：AMI PHARM CO., LTD.

  公开号：US20190201328A1

  公开（公告）日：2019-07-04

  The present invention relates to a composition comprising glycocholic acid or taurocholic acid and phosphatidylcholine at a particular mixing ratio for reducing localized fat without side effects such as a pain, edema, necrosis of muscle cells, fibroblasts and vascular endothelial cells other than adipocytes, anesthesia of administration sites, extensive swelling, erythema, induration, paresthesia, nodule, pruritus, burning sensation, nerve injury, and dysphagia, and a method for preparing the same. The inventor has found that the effect of PPC injectable composition on fat reduction may be reduced or enhanced during its subcutaneous administration, depending on the types of solubilizing agents, especially the types of bile acids, which are combined so as to prepare a safe and stable PPC injection using insoluble PPC. The PPC injectable composition solubilized with GCA or TCA selectively reduces adipocytes without inducing necrosis of fibroblasts, muscle cells and vascular endothelial cells, thereby alleviating the known clinical side effects.
• [EN] STEROL ANALOGS AND USES THEREOF<br/>[FR] ANALOGUES DE STÉROL ET LEURS UTILISATIONS
  申请人：MODERNATX INC

  公开号：WO2020061332A1

  公开（公告）日：2020-03-26

  The invention relates to compositions and methods for the preparation, manufacture, and therapeutic use of compositions comprising mRNA and a lipid nanoparticle comprising a compound of the invention and an ionizable lipid.